翰森制药(03692.HK) 公布,创新药昕越(伊奈利珠单抗注射液)的第二项上市许可申请获国家药品监督管理局受理,用于治疗免疫球蛋白G4相关性疾病。该适应症已获纳入优先审评审批程序。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-04 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.